“Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response.” NATURE COMMUNICATIONS. May 2019

"Preclinical evaluation of mesothelin-specific T cell receptor (TCR) fusion constructs (TRuC™s) utilizing the signaling power of the complete TCR complex: A new opportunity for solid tumor therapy." CANCER RESEARCH. July 2018 

"Characterization of a novel class of engineered (TCR) fusion constructs (TRuC™s) aimed to treat solid tumors." CANCER RESEARCH. July 2018

"Novel T Cell Receptor Fusion Constructs TRuC (TM) Polypeptides Utilizing the Signaling Power of the Complete TCR Complex for Solid Tumor Therapy." MOLECULAR THERAPY. May 2018

"Characterization of Mesothelin-Specific T Cell Receptor Fusion Construct (TRuC (TM)) Expressing T Cells for the Treatment of Solid Tumors."  MOLECULAR THERAPY. May 2018



Importance of TCR function and TCR subunits

Guy, Clifford S., et al. "Distinct TCR signaling pathways drive proliferation and cytokine production in T cells." Nature Immunology 14.3 (2013): 262.

Kuhns, Michael S., and Mark M. Davis. "TCR signaling emerges from the sum of many parts." Frontiers in Immunology 3 (2012): 159.

Minguet, Susana, et al. "Full activation of the T cell receptor requires both clustering and conformational changes at CD3." Immunity 26.1 (2007): 43-54.


Role of HLA in immunity and cancer surveillance

Garrido, Federico, et al. "The urgent need to recover MHC class I in cancers for effective immunotherapy." Current Opinion in Immunology 39 (2016): 44-51.

Hicklin, Daniel J., Francesco M. Marincola, and Soldano Ferrone. "HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story." Molecular Medicine Today 5.4 (1999): 178-186.

Leone, Patrizia, et al. "MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells." Journal of the National Cancer Institute 105.16 (2013): 1172-1187.


Effectiveness and limitations of current adoptive T cell therapies

Bonifant, Challice L., et al. "Toxicity and management in CAR T-cell therapy." Molecular Therapy-Oncolytics 3 (2016).

Lu, Yong-Chen, et al. "Treatment of patients with metastatic cancer using a major histocompatibility complex class II–restricted T-cell receptor targeting the cancer germline antigen MAGE-A3." Journal of Clinical Oncology 35.29 (2017): 3322-3329.

Maus, Marcela V., and Carl H. June. "Making better chimeric antigen receptors for adoptive T-cell therapy." Clinical Cancer Research; 22.8 (2016): 1875-1884

Neelapu, Sattva S., et al. "Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma." New England Journal of Medicine 377.26 (2017): 2531-2544

Park, Jae H., et al. "Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia." New England Journal of Medicine 378.5 (2018): 449-459.


Costs associated with current CAR-T treatment

Institute for Clinical and Economic Review. “CAR-T Therapies: Final Evidence Report.” Published March 23, 2018

Whittington, Melanie D., Daniel A. Ollendorf, and Jonathan D. Campbell. "Accounting for All Costs in the Total Cost of Chimeric Antigen Receptor T-Cell Immunotherapy." JAMA Oncology (2018)


Importance of T cell metabolism

Buck, Michael D., et al. "Mitochondrial dynamics controls T cell fate through metabolic programming." Cell 166.1 (2016): 63-76.

Rivadeneira, Dayana B., and Greg M. Delgoffe. "Antitumor T-cell Reconditioning: Improving Metabolic Fitness for Optimal Cancer Immunotherapy." Clinical Cancer Research (2018). 


Mesothelin expression is associated with a worse prognosis

Kachala, Stefan S., et al. "Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma." Clinical cancer research 20.4 (2014): 1020-1028.

Cristaudo, Alfonso, et al. "Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer." Clinical Cancer Research 13.17 (2007): 5076-5081.

This page contains links to sites at which articles written by persons not affiliated with TCR² are available for purchase. The third-party articles referenced in this Publications section are identified for background purposes only, and TCR² does not purport that they represent a complete survey of the relevant science. The views expressed in the articles are those of their respective authors and do not reflect the views of TCR². TCR² has not independently verified any of the information contained in the third-party articles and disavows any obligation to update or correct the information contained in these articles.